Merck & Co. has gained 55% over the past year, driven by investor optimism about its strategy to offset revenue losses from Keytruda's patent expiry in 2028. The company has diversified its pipeline through acquisitions and partnerships with firms like Terns Pharma and Daiichi Sankyo. Analysts project that by 2030, new products could generate around $17.35 billion in revenue, potentially boosting Merck's valuation by 15% above current levels. Despite an expected revenue dip post-2028, Merck's proactive research and development efforts position it for steady growth and resilience in the pharmaceutical sector.
The Schwab U.S. Dividend Equity ETF (SCHD) focuses on 100 stocks with strong dividend histories, offering retirees a reliable income with a 3.27% yield and low fees. However, its top 10 holdings make up 41% of the fund, exposing investors to higher s...
Pfizer and Merck reported earnings that highlight their differing dividend and growth profiles for 2026. Pfizer offers a strong 6.58% dividend yield backed by solid earnings and a focus on cost savings and new drug launches, prioritizing income over ...
